Lisata Therapeutics, Inc. (LSTA) Stock Price & Analysis
Lisata Therapeutics, Inc. (LSTA) closed at USD 1.07 on Thursday, October 15, 2026, up 4.90% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.02; the Oct 15, 2026 session ranged USD 1–1.07 on volume of 23,165 shares. Market capitalization is $11.56M, with a 52-week range of USD 0.98–5.07 (NCM). Source: Nexqual, retrieved October 16, 2026 at 07:25 UTC.
Also available as compact Markdown for AI agents: nexqual.com/LSTA.md
Key facts (LSTA)
- Analysts: Hold (mean 3.00 on a 1–5 scale) (2 analysts).
- Total return with dividends: 1Y -57.5% vs S&P 500 +18.1%; 5Y -94.2% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD —, revenue estimate $0K.
Analysts (LSTA)
Consensus Hold (mean 3.00 on a 1–5 scale), 2 analysts.
Total return (dividends reinvested) (LSTA)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -57.5% | -94.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -57.7% | -43.3% |
| Volatility (annualized) | 117.7% | 81.3% |
| Max drawdown | -80.4% (Mar 2026→Jul 2026) | -94.6% (Oct 2021→Jul 2026) |
Key Statistics (as of October 16, 2026 at 07:25 UTC)
| Price | USD 1.07 |
|---|---|
| Change | ▲ 4.90% (up) |
| Previous Close | USD 1.02 |
| Open | USD 1.05 |
| Day Range | USD 1 – 1.07 |
| 52-Week Range | USD 0.98 – 5.07 |
| Volume | 23,165 shares |
| Market Cap | $11.56M |
| Exchange | NCM |
Technical Analysis (LSTA)
Nexqual's technical model rates LSTA "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 07:25 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 34.3 (neutral) |
| vs SMA50 | Below (USD 1.41) |
| MACD | -0.15 (negative) |
Analyst Ratings (LSTA)
Wall Street analysts rate LSTA "Hold" based on 2 analysts, per Nexqual as of October 16, 2026 at 07:25 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 2 |
| Buy / Hold / Sell | 0 / 2 / 0 |
Earnings (LSTA)
| Next Earnings Date | 2026-11-05 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD -0.49 vs est -0.54 ▲ beat |
| 2025-06-30 | USD -0.54 vs est -0.65 ▲ beat |
| 2025-03-31 | USD -0.55 vs est -0.53 ▼ miss |
Source: Nexqual, October 16, 2026 at 07:25 UTC.
Financials & Fundamentals (LSTA)
| Total Revenue | $100,000 |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -16426.00% |
| Profit Margin | +0.00% |
| ROE | -101.66% |
| Current Ratio | 3.69 |
| Total Cash | $10.44M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 07:25 UTC.
Financial Health Score (LSTA)
Nexqual rates Lisata Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 07:25 UTC.
| Growth | Critical — Revenue -83% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $10M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$12M (TTM) |
| Efficiency | Critical — ROE -102%, ROA -56.7% |
Ownership (LSTA)
| Insider Ownership | +22.26% |
|---|---|
| Institutional Ownership | +11.12% |
| Shares Outstanding | 10.80M |
| Float | 6.76M |
| Short % of Float | +0.43% |
Source: Nexqual, October 16, 2026 at 07:25 UTC.
Leadership (LSTA)
Lisata Therapeutics, Inc. is led by David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc. (age 68), CEO & Director, per Nexqual as of October 16, 2026 at 07:25 UTC.
| CEO & Director | David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc. (age 68) |
|---|---|
| President & COO | Joshua Lehrer-Graiwer FACC (age 51) |
Major Backers & Investors (LSTA)
Notable institutional backers of Lisata Therapeutics, Inc. include Yakira Capital Management, Inc., Deeter Investments Llp, CSS LLC, according to Nexqual as of October 16, 2026 at 07:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Yakira Capital Management, Inc. | 1.54% |
| Deeter Investments Llp | 1.32% |
| CSS LLC | 1.23% |
| Deltec Asset Management LLC | 0.92% |
| Rangeley Capital, LLC | 0.9% |
| Virtu Financial LLC | 0.65% |
| Fidelity | 0.64% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.72% |
| Geode Capital | 0.81% |
| BlackRock | 0.61% |
Source: Nexqual, October 16, 2026 at 07:25 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 07:25 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt